AHR and myeloid sarcoma: In this line, we speculate that reduced AHR signalling in chronic stages of MS leads to the loss of neuroprotective astrocyte activation states, accompanied by a reduction in astrocyte-derived PTN in cortical layers, which ultimately results in the perpetuation of CNS inflammation and disease progression.